Management

Prof. Dr. Wolfgang Meyer-Sabellek, M.D., FACC

Member of the Executive Board since 2009
Medical Doctor, Nephrologist & Cardiologist at the J.W. Goethe-University (Frankfurt/M) and USC-Medical Center (Los Angeles)
Professorship for Internal Medicine at the Free University & Humboldt University (CHARITE, Berlin)
Prior VP Global Development CV Boehringer Mannheim (later Roche). Under his responsibility blockbusters were developed (e.g., Carvedilol, Torasemide & Reteplase)
Appointed as Medical Director Germany/Switzerland/ Austria for Astra, later AstraZeneca, being responsible for R&D and Regulatory for Phase II-IV and member of the international AstraZeneca board to approve blockbuster Symbicort in the indication COPD & Asthma
Prior advisor to the FDA and member of the German BfArM off-label expert group

20 years experience in financing & controlling
Member of the management board of the listed bmp Beteiligungsmanagement AG since 2011
Former member of the management board of the listed bmp media Investors AG 1999-2011
Prior to this commitment engaged with Berliner Volksbank eG, financing of seed, start-up and expansion projects
Also member of the management board of two private equity retail funds since 2005
Substantial experience in capital market transactions

Biologist with a continuous strong scientific interest in inflammation, PhD thesis at Medical School Hannover
13 years experience in pharmaceutical research and development from early drug discovery through to clinical proof of concept
Postdoctoral Scientist, Novartis Research Institute Vienna (Austria); investigating inflammatory targets (cytokines & chemokines)
Joined Revotar Biopharmaceuticals in 2001 as Senior Scientist. Successfully established the Bioassay Department
2004-2008, Head of Biology of Revotar
2008-2011, Director Preclinical R&D and Director Clinical Development of Revotar and member of Revotars Strategic Review Team (SRT)
Since 2011, Chief Scientific Officer of Revotar